全文获取类型
收费全文 | 544篇 |
免费 | 43篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 27篇 |
妇产科学 | 22篇 |
基础医学 | 94篇 |
口腔科学 | 48篇 |
临床医学 | 46篇 |
内科学 | 90篇 |
皮肤病学 | 18篇 |
神经病学 | 25篇 |
特种医学 | 13篇 |
外科学 | 47篇 |
综合类 | 9篇 |
预防医学 | 58篇 |
眼科学 | 7篇 |
药学 | 32篇 |
中国医学 | 2篇 |
肿瘤学 | 44篇 |
出版年
2023年 | 7篇 |
2022年 | 7篇 |
2021年 | 18篇 |
2020年 | 8篇 |
2019年 | 16篇 |
2018年 | 19篇 |
2017年 | 18篇 |
2016年 | 18篇 |
2015年 | 17篇 |
2014年 | 28篇 |
2013年 | 27篇 |
2012年 | 49篇 |
2011年 | 44篇 |
2010年 | 27篇 |
2009年 | 17篇 |
2008年 | 33篇 |
2007年 | 37篇 |
2006年 | 42篇 |
2005年 | 19篇 |
2004年 | 16篇 |
2003年 | 24篇 |
2002年 | 13篇 |
2001年 | 12篇 |
2000年 | 11篇 |
1999年 | 5篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 5篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1986年 | 5篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 4篇 |
1976年 | 5篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1971年 | 4篇 |
1969年 | 2篇 |
排序方式: 共有590条查询结果,搜索用时 15 毫秒
581.
582.
The pathogenic potential of the rapidly growing mycobacteria (RGM) has started being recognized. This is due to more sensitive and specific techniques in the laboratory. The RGM are generally defined as nontuberculous species of mycobacteria that show visible growth on agar media within 7 days. RGM are widely distributed in nature and have been isolated from natural water, tap water, and soil. Several biochemical tests, high performance liquid chromatography, and molecular techniques have been developed for rapid identification of these species. The American Thoracic Society and the Infectious Disease Society of America recommend that RGM should be identified to the species level using a recognized acceptable methodology such as polymerase chain reaction restriction enzyme analysis or biochemical testing and routine susceptibility testing of RGM should include amikacin, imipenem, doxycycline, the fluorinated quinolones, a sulphonamide or trimethoprim-sulphamethoxazole, cefoxitin, clarithromycin, linezolid, and tobramycin. The diseases caused by these organisms have varied manifestations. They have been responsible for a number of healthcare-associated outbreaks and pseudo-outbreaks. For recognition of outbreaks, it is important to be familiar with the causative organisms like RGM which are most frequently involved in healthcare-associated outbreaks and pseudo outbreaks. It is essential to intervene as soon as possible to interrupt this transmission. Large gaps still exist in our knowledge of RGM. Unquestionably more studies are required. Through this review, we wish to emphasize that reporting of RGM from clinical settings along with their sensitivity patterns is an absolute need of the hour. 相似文献
583.
Iron deficiency anemia is commonly encountered in outpatient practice. Gastric acid is one of the important factors for optimum absorption of iron. Proton pump inhibitors are very commonly prescribed medications. One of the debated effects of proton pump inhibitors is on oral iron absorption. Their effect on absorption of oral iron supplementation in iron-deficient patients has not been studied. At the Cooper Hematology Outpatient office, we reviewed charts of iron-deficient anemic patients who were on omeprazole for the last 4 years. Fifty patients having no apparent ongoing blood loss, having other causes of anemia especially that of chronic diseases ruled out, and on omeprazole while starting ferrous sulfate therapy for iron deficiency were selected for chart review. The iron-study results at the start of oral ferrous sulfate therapy and at 3 months follow-up were compared to evaluate the response of ferrous sulfate. The mean hemoglobin change was 0.8 ± 1.2 g/L. The mean change in ferrtin values was 10.2 ± 7.8 μg/L. Only 16% of the patients had a normal response to hemoglobin levels (rise of >2 g/dL), and only 40% had a normal response to ferritin levels (rise of >20 μg/dL). The average age of patients having a suboptimal response to both hemoglobin and ferritin was significantly higher compared with that of the patients with an optimal response. Omeprazole and possibly all proton pump inhibitors decrease the absorption of oral iron supplementation. Iron-deficient patients taking proton pump inhibitors may have to be treated with high dose iron therapy for a longer duration or with intravenous iron therapy. 相似文献
584.
Hande AH Gadbail AR Sonone AM Chaudhary MS Wadhwan V Nikam A 《Archives of oral biology》2011,(12):1635-1640
Objective
The aim of the present study was to evaluate and compare the expression of CD105 (endoglin) in solid multicystic ameloblastoma (SMA) and unicystic ameloblastoma (UA).Materials and methods
Angiogenesis was assessed in 20 SMA, 15 UA and 10 normal oral mucosa samples by measuring the mean vascular density (MVD), total vascular area (TVA) and mean vascular area (MVA). The immunohistochemistry was carried out by using monoclonal mouse anti-human antibody against CD105.Results
The Kruskal–Wallis test showed significant difference in mean MVD, TVA, and MVA between SMA, UA, and control group (p < 0.001). Using the Mann–Whitney test, the mean MVD, TVA and MVA, was statistically significant between SMA and control group (p < 0.001) as well as between UA and control group (p < 0.001). No significant difference of mean MVD, TVA, and MVA, was observed between SMA and UA (p > 0.05).Conclusion
Our study results show no significant difference in MVD, TVA and MVA between SMA and UA. This may reflect the fact that though clinical behaviour, histopathological presentation and prognosis of SMA and UA differ, the process of angiogenesis is not different. This suggests that the angiogenesis has an important role in tumour progression and invasiveness of ameloblastoma. Measurement and assessment of tumour angiogenesis may prove very valuable in predicting response to antiangiogenic therapeutic strategies and also provide objective assessment of post therapeutic response particularly in recurrent cases of SMA and UA. 相似文献585.
586.
587.
Cumberbatch M Singh M Dearman RJ Young HS Kimber I Griffiths CE 《The Journal of experimental medicine》2006,203(4):953-960
We have examined whether psoriasis is associated with systemic effects on epidermal Langerhans cell (LC) function and, specifically, the migration of LCs from the skin. Compared with normal skin, the frequency and morphology of epidermal LCs in uninvolved skin from patients with psoriasis was normal. However, mobilization of these cells in response to stimuli that normally induce migration (chemical allergen, tumor necrosis factor alpha [TNF-alpha], and interleukin-1beta [IL-1beta]) was largely absent, despite the fact that treatment with TNF-alpha and IL-1beta was associated with comparable inflammatory reactions in patients and controls. The failure of LC migration from uninvolved skin was not attributable to altered expression of receptors for IL-1beta or TNF-alpha that are required for mobilization, nor was there an association with induced cutaneous cytokine expression. Although a role for altered dynamics of LC migration/turnover has not been formally excluded, these data reveal a very consistent decrement of LC function in psoriasis that may play a decisive role in disease pathogenesis. 相似文献
588.
Maximilian Stahl Andriy Derkach Noushin Farnoud Jan Philipp Bewersdorf Troy Robinson Christopher Famulare Christina Cho Sean Devlin Kamal Menghrajani Minal A. Patel Sheng F. Cai Linde A. Miles Robert L. Bowman Mark B. Geyer Andrew Dunbar Zachary D. Epstein-Peterson Erin McGovern Jessica Schulman Jacob L. Glass Justin Taylor Aaron D. Viny Eytan M. Stein Bartlomiej Getta Maria E. Arcila Qi Gao Juliet Barker Brian C. Shaffer Esperanza B. Papadopoulos Boglarka Gyurkocza Miguel-Angel Perales Omar Abdel-Wahab Ross L. Levine Sergio A. Giralt Yanming Zhang Wenbin Xiao Nidhi Pai Elli Papaemmanuil Martin S. Tallman Mikhail Roshal Aaron D. Goldberg 《American journal of hematology》2023,98(1):79-89
Measurable residual disease (MRD) is a powerful prognostic factor in acute myeloid leukemia (AML). However, pre-treatment molecular predictors of immunophenotypic MRD clearance remain unclear. We analyzed a dataset of 211 patients with pre-treatment next-generation sequencing who received induction chemotherapy and had MRD assessed by serial immunophenotypic monitoring after induction, subsequent therapy, and allogeneic stem cell transplant (allo-SCT). Induction chemotherapy led to MRD− remission, MRD+ remission, and persistent disease in 35%, 27%, and 38% of patients, respectively. With subsequent therapy, 34% of patients with MRD+ and 26% of patients with persistent disease converted to MRD-. Mutations in CEBPA, NRAS, KRAS, and NPM1 predicted high rates of MRD− remission, while mutations in TP53, SF3B1, ASXL1, and RUNX1 and karyotypic abnormalities including inv (3), monosomy 5 or 7 predicted low rates of MRD− remission. Patients with fewer individual clones were more likely to achieve MRD− remission. Among 132 patients who underwent allo-SCT, outcomes were favorable whether patients achieved early MRD− after induction or later MRD− after subsequent therapy prior to allo-SCT. As MRD conversion with chemotherapy prior to allo-SCT is rarely achieved in patients with specific baseline mutational patterns and high clone numbers, upfront inclusion of these patients into clinical trials should be considered. 相似文献
589.